Further, E6AP can suppress the metastasis suppressor n-Myc downstream regulated 1 (NDRG1) in mesenchymal phenotypes of prostate cancer where stabilization of NDRG1, via pharmacological inhibition of E6AP, has been proposed for prostate cancer therapy [56]. Here, UBE3A is linked to prostate carcinoma.